<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005892</url>
  </required_header>
  <id_info>
    <org_study_id>199/15100</org_study_id>
    <secondary_id>UMN-MT-1985-01</secondary_id>
    <secondary_id>UMN-MT-8501</secondary_id>
    <nct_id>NCT00005892</nct_id>
  </id_info>
  <brief_title>Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fairview University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:

      I. Determine the effectiveness of moderate dose cyclophosphamide and radiotherapy in terms of
      improving survival and reducing the morbidity following allogeneic bone marrow
      transplantation in patients with myelodysplastic syndrome and acute leukemia related to
      Fanconi's anemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:

      Patients receive cyclophosphamide IV over 1-2 hours on day -6 through -3 and total body
      radiotherapy on day -1. Patients undergo allogeneic bone marrow transplantation on day 0.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2000</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Fanconi's Anemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Leukemia, Nonlymphocytic, Acute</condition>
  <condition>Leukemia, Lymphocytic, Acute</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Diagnosis of Fanconi's anemia with the family history and typical phenotype including:
             Short stature Hypoplastic radii Skin pigmentation Renal anomalies Chromosomal
             fragility

          -  Evidence of Fanconi's myelodysplastic syndrome Bone marrow dysplasia of all 3 marrow
             cell lines AND Clonal cytogenetic abnormalities demonstrable in marrow cells

          -  First complete remission following therapy for Fanconi's acute leukemia allowed

          -  Must have related histocompatible donor No evidence of excessive in vitro chromosome
             fragility typical of Fanconi's anemia Normal CBC and bone marrow
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J. Weisdorf</last_name>
    <role>Study Chair</role>
    <affiliation>Fairview University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fairview University Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2004</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2000</study_first_submitted>
  <study_first_submitted_qc>June 2, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Fanconi's anemia</keyword>
  <keyword>acute leukemia</keyword>
  <keyword>acute lymphocytic leukemia</keyword>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>aplastic anemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>de novo myelodysplastic syndrome</keyword>
  <keyword>hematologic disorders</keyword>
  <keyword>hematopoietic/lymphoid cancer</keyword>
  <keyword>leukemia</keyword>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>oncologic disorders</keyword>
  <keyword>previously treated myelodysplastic syndrome</keyword>
  <keyword>rare disease</keyword>
  <keyword>secondary myelodysplastic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

